Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of the Safety and Efficacy of a Modified Vaccinia Virus (BT-001) Delivered by Endoscopic Intra-tumoural Injection Followed by Systemic Antiprogammed Death-1 (Anti-PD-1) Antibodies in Patients With Localised Rectal Cancer With Proficient Mismatch Repair (pMMR)

NCT07687875 is registered in ClinicalTrials.gov with Henry Smith as lead sponsor.

NCT NCT07687875
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07687875 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of the Safety and Efficacy of a Modified Vaccinia Virus (BT-001) Delivered by Endoscopic Intra-tumoural Injection Followed by Systemic Antiprogammed Death-1 (Anti-PD-1) Antibodies in Patients With Localised Rectal Cancer With Proficient Mismatch Repair (pMMR)
Lead sponsor
Henry Smith
Phase
Phase 1
Overall status
Recruiting
Start date
June 17, 2026
Completion date
December 31, 2033
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

rectal cancer patients